Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurobiological Technologies has received approximately $2.1 million from Merz Pharmaceuticals for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease for the quarter ended September 30, 2007.
Subscribe to our email newsletter
Under an exclusive marketing agreement, Neurobiological receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners.
Paul Freiman, president and CEO of Neurobiological, said: “This royalty payment helps provide funding for our ongoing clinical program for Viprinex (ancrod) and contributes to our strong financial position.”